What is the total amount of financing BeOne Medicines has secured through this Facilities Agreement?

BeOne Medicines has secured approximately $990 million in senior secured financing. This is comprised of $140 million under the B1 Revolving Loan Facility, $560 million under the B2 Term Loan Facility, and approximately $300 million under the A Term Loan Facility.

How will the proceeds from this financing be used?

The proceeds from the A Loan Facility are for general corporate purposes, including financing working capital, refinancing existing offshore financial indebtedness, and paying associated fees. The B Loan Facilities are also for general corporate purposes, including working capital, refinancing existing offshore financial indebtedness, paying fees, and reimbursing prior payments for these purposes.

What is the security backing these loan facilities?

The loan facilities are secured on a first-priority basis by a security interest in the equity interests of a subsidiary and security interests in, and a mortgage on, the Company's manufacturing and clinical R&D facility located in New Jersey. Certain subsidiaries also provide unconditional guarantees.

What are the key financial covenants associated with this new debt facility?

Key financial covenants include maintaining a minimum cash interest coverage ratio of 5.00:1.00, a net leverage ratio not greater than 2.50:1.00, a minimum total consolidated shareholders’ equity of $2.7 billion, a minimum cash balance held outside the PRC of $500.0 million, a maximum financial indebtedness of $2.0 billion for the Company and its subsidiaries, and a maximum financial indebtedness of $500.0 million for PRC-incorporated subsidiaries.

ONC/BEIGF 8-K: Material Agreements & Financial Events

Summary

BeOne Medicines Ltd. (ONC) has announced the execution of a significant Facilities Agreement, securing senior secured financing totaling approximately $990 million. This facility includes a $140 million B1 Revolving Loan Facility and a $560 million B2 Term Loan Facility, both denominated in U.S. dollars, along with a $300 million A Term Loan Facility denominated in Renminbi. The funds are earmarked for general corporate purposes, including working capital, refinancing existing offshore debt, and associated fees. This substantial debt financing provides BeOne Medicines with considerable financial flexibility to support its ongoing operations and strategic initiatives. The agreement also outlines specific terms regarding loan utilization, maturity dates (36 months for the A Loan, 24 months for B Loans), interest rates (RMB Reference Rate + 0.65% for A Loan, USD Reference Rate + 2.40% for B Loans), and repayment schedules. The loan facilities are secured by equity interests in a subsidiary and the Company's New Jersey manufacturing and R&D facility, with guarantees from certain subsidiaries. The agreement includes customary covenants and events of default, as well as provisions for voluntary prepayments and mandatory prepayments under certain circumstances like a change of control.

Key Highlights

1BeOne Medicines Ltd. has secured approximately $990 million in senior secured financing through a new Facilities Agreement.
2The financing comprises a $140 million B1 Revolving Loan Facility, a $560 million B2 Term Loan Facility (both USD-denominated), and a $300 million A Term Loan Facility (RMB-denominated).
3Proceeds are designated for general corporate purposes, including working capital and refinancing existing debt.
4The A Loan Facility matures in 36 months, while the B Loan Facilities mature in 24 months from their respective utilization dates.
5Interest rates are variable: RMB Reference Rate + 0.65% for the A Loan and USD Reference Rate + 2.40% for the B Loans.
6The loan facilities are secured by equity interests and the Company's New Jersey manufacturing and R&D facility.
7The agreement includes significant financial covenants, such as minimum cash interest coverage ratio, net leverage ratio, and minimum shareholders' equity, aimed at maintaining financial health.

BeOne Medicines Ltd. 8-K Report, Material Agreement (Nov 19, 2025)

Summary

Key Highlights

Frequently Asked Questions